Pharmacovigilance is the science and practice of monitoring, evaluating, and managing the safety of medicinal products. It is essential to ensure that the benefits of a product outweigh its risks, and to identify and prevent any adverse effects or interactions that may occur in the postmarketing phase. One of the key documents that guides pharmacovigilance activities is the ICH E2E guideline, which stands for International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use – Pharmacovigilance Planning.
The ICH E2E guideline provides a framework for planning and conducting pharmacovigilance activities, especially for the early postmarketing period of a new product. It applies to chemical entities, biotechnology-derived products, and vaccines. In this article, we will discuss the scope and importance of the ICH E2E guideline for pharmacovigilance practice.
The Safety Specification
The first component of the ICH E2E guideline is the Safety Specification, which is a summary of the product’s risk profile based on preclinical and clinical data, as well as any relevant information from similar products or classes of products. It identifies the important identified risks, important potential risks, and important missing information that need to be addressed in the postmarketing phase.
The Safety Specification helps to define the safety objectives and priorities for the product, and to design the appropriate pharmacovigilance methods and tools. It also helps to communicate the safety profile of the product to different stakeholders, such as regulators, health professionals, or patients.
The Safety Specification should include the following elements:
- A description of the product’s indication, dosage, route of administration, and target population
- A summary of the product’s pharmacology, pharmacokinetics, and pharmacodynamics
- A summary of the product’s preclinical safety data, including animal toxicology, genotoxicity, carcinogenicity, reproductive toxicity, and immunogenicity
- A summary of the product’s clinical safety data, including adverse reactions, interactions, contraindications, warnings, precautions, and special populations
- A comparison of the product’s safety profile with similar products or classes of products
- An identification and description of the important identified risks, important potential risks, and important missing information
